Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brittany Chapman

Neurology Louisville, KY Medical Doctor

NPI 1417119082 CMS profile 602668

401 E Chestnut St Unit 510, Louisville, KY 40202

Open in the dashboard

General payments

$8,839

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Chapman of Louisville, KY is reported in the CMS Open Payments database as having received $8,839 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $95 1
2023 General $1,789 22
2022 General $607 26
2021 General $805 24
2020 General $835 33
2019 General $4,708 119

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Chapman
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Brittany Chapman were reported at $95. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Brittany Chapman Neurology median Middle half National median
2019 $4,708 $474 $118–$2,177 $163
2020 $835 $367 $82–$2,309 $114
2021 $805 $438 $104–$2,547 $132
2022 $607 $442 $103–$2,388 $149
2023 $1,789 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $95 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. LivaNova USA, Inc. $3,535 29 payments
  2. NeuroPace, Inc. $2,155 24 payments
  3. UCB, Inc. $465 22 payments
  4. Sunovion Pharmaceuticals Inc. $376 24 payments
  5. AbbVie, Inc. $256 12 payments
  6. SK Life Science, Inc. $199 3 payments
  7. Eisai Inc. $195 10 payments
  8. Supernus Pharmaceuticals, Inc. $187 33 payments
  9. ACADIA Pharmaceuticals Inc $186 6 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $140 5 payments
  11. Other $1,144 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,330 216 payments
  2. Travel and Lodging $2,496 8 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13 1 payment
Products named General payments · program years 2019–2025
  1. VNS Therapy $2,863 17 payments
  2. RNS System Epilepsy $1,854 19 payments
  3. APTIOM $340 22 payments
  4. VNS - Sentiva $329 5 payments
  5. RNS System Epilepsy $302 5 payments
  6. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $248 6 payments
  7. Briviact $218 14 payments
  8. Fycompa $195 10 payments
  9. NUPLAZID $186 6 payments
  10. XCOPRI $182 2 payments
  11. Other $2,269 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

570

Median for Neurology: 833

Drug cost

$94,842

Median for Neurology: $202,670

Branded share of claims

21.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 23 $38,345
Vimpat Lacosamide Brand 19 $18,221
Dilantin Phenytoin Sodium Extended Brand 22 $7,537
Divalproex Sodium Generic 41 $6,988
Clobazam Generic 28 $3,770
Lacosamide Generic 38 $3,434
Carbamazepine Generic 11 $2,932
Levetiracetam Er Levetiracetam Brand 20 $2,828
Levetiracetam Generic 76 $2,222
Carbamazepine Er Carbamazepine Brand 16 $2,128

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$13,953

Medicare's payments for the services billed

Medicare patients

128

Average age 74

Services billed

220

71 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 39%
Chronic kidney disease 39%
Depression 38%
Ischemic heart disease 36%
Alzheimer's or dementia 32%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record